Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/76525
Title:
Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
Authors:
Howe, M C; Chapman, A; Kerr, K; Dougal, Mark; Anderson, Heather; Hasleton, Philip S
Abstract:
AIMS: Histopathologists report the presence of neuroendocrine (NE) differentiation in non-small cell lung carcinoma (NSCLC) in up to a third of cases and are often questioned about its clinical relevance. The conclusions of previous studies have been inconsistent. This paper aims to provide an answer by examining a large series together with a comprehensive critique of the literature. METHODS AND RESULTS: Four hundred and thirty-nine cases of NSCLC were examined, immunohistochemically, using antibodies to chromogranin A (CGA), synaptophysin (SYN) and CD56/neural cell adhesion molecule (NCAM). Three hundred and forty-one cases had been treated with surgical resection and the remainder with chemotherapy. The results were compared with clinical outcome. Thity-six percent of cases had positive staining for at least one NE marker. CGA was positive in 5.5% of cases, SYN in 16.5% and NCAM in 28%. There was no association between the presence of NE markers and survival in either the surgically treated group or the chemotherapy-treated group. There was also no association between NE markers and response to chemotherapy in the latter group. CONCLUSIONS: The presence of immunohistochemically detected NE differentiation in NSCLC is not of prognostic significance.
Affiliation:
Department of Histopathology, South Manchester University Hospital, Manchester, UK. miles.howe@smuht.nwest.nhs.uk
Citation:
Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. 2005, 46 (2):195-201 Histopathology
Journal:
Histopathology
Issue Date:
Feb-2005
URI:
http://hdl.handle.net/10541/76525
DOI:
10.1111/j.1365-2559.2005.02047.x
PubMed ID:
15693892
Type:
Article
Language:
en
ISSN:
0309-0167
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowe, M C-
dc.contributor.authorChapman, A-
dc.contributor.authorKerr, K-
dc.contributor.authorDougal, Mark-
dc.contributor.authorAnderson, Heather-
dc.contributor.authorHasleton, Philip S-
dc.date.accessioned2009-08-06T14:40:58Z-
dc.date.available2009-08-06T14:40:58Z-
dc.date.issued2005-02-
dc.identifier.citationNeuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. 2005, 46 (2):195-201 Histopathologyen
dc.identifier.issn0309-0167-
dc.identifier.pmid15693892-
dc.identifier.doi10.1111/j.1365-2559.2005.02047.x-
dc.identifier.urihttp://hdl.handle.net/10541/76525-
dc.description.abstractAIMS: Histopathologists report the presence of neuroendocrine (NE) differentiation in non-small cell lung carcinoma (NSCLC) in up to a third of cases and are often questioned about its clinical relevance. The conclusions of previous studies have been inconsistent. This paper aims to provide an answer by examining a large series together with a comprehensive critique of the literature. METHODS AND RESULTS: Four hundred and thirty-nine cases of NSCLC were examined, immunohistochemically, using antibodies to chromogranin A (CGA), synaptophysin (SYN) and CD56/neural cell adhesion molecule (NCAM). Three hundred and forty-one cases had been treated with surgical resection and the remainder with chemotherapy. The results were compared with clinical outcome. Thity-six percent of cases had positive staining for at least one NE marker. CGA was positive in 5.5% of cases, SYN in 16.5% and NCAM in 28%. There was no association between the presence of NE markers and survival in either the surgically treated group or the chemotherapy-treated group. There was also no association between NE markers and response to chemotherapy in the latter group. CONCLUSIONS: The presence of immunohistochemically detected NE differentiation in NSCLC is not of prognostic significance.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshCarcinoma, Large Cell-
dc.subject.meshCarcinoma, Neuroendocrine-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshCell Differentiation-
dc.subject.meshChromogranin A-
dc.subject.meshChromogranins-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeural Cell Adhesion Molecules-
dc.subject.meshPrognosis-
dc.subject.meshSurvival Analysis-
dc.subject.meshSynaptophysin-
dc.titleNeuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Histopathology, South Manchester University Hospital, Manchester, UK. miles.howe@smuht.nwest.nhs.uken
dc.identifier.journalHistopathologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.